



ASX/MEDIA RELEASE

3rd April 2017

SARAH Abstract Embargoed Until EASL/ILC Meeting

Sydney, Australia; 3rd April 2017 – Sirtex Medical Limited (ASX:SRX) today announces the SARAH study abstract has been embargoed ahead of the upcoming European Association for the Study of the Liver, International Liver Congress™ (EASL/ILC) in Amsterdam, the Netherlands from 19th-23rd April 2017. The abstract is expected to be released by EASL/ILC on the day of the presentation of the SARAH study data.

The SARAH study has been awarded an Oral Abstract at the meeting and will be presented in the General Session III on Saturday, 22nd April 2017 between 10-10:15 am local time. The Oral Abstract is entitled “SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma.”

Details of the EASL/ILC 2017 Press Programme can be found at the following link: <https://ilc-congress.eu/pressprogramme/>

About EASL/ILC

The European Association for the Study of the Liver (EASL) is a European professional association for liver disease. EASL has evolved into a major European association with international influence dedicated to the liver and liver disease. EASL has over 4,000 members from all over the world and provides an annual platform, The International Liver Congress™ (ILC), which is a high calibre and multi-disciplinary scientific Congress attracting over 10,000 delegates annually. The Congress fosters advances in hepatology (liver research) and unveils new and exciting data on the liver. 2017 is EASL's 52nd annual Congress.

About SARAH

SARAH (Sorafenib versus Radioembolisation in Advanced Hepatocellular carcinoma) is a Phase III multi-centre prospective randomised open-label study for patients in France with advanced HCC (Barcelona Clinic Liver Cancer stage C) with or without portal vein thrombosis and no extrahepatic spread, or whose disease has progressed or recurred after previous therapies; and who are ineligible for surgical resection, ablation or liver transplantation.

The primary goal of the SARAH study is to assess if radioembolisation with SIR-Spheres® Y-90 resin microspheres provides an increased survival benefit compared to sorafenib in patients with advanced HCC. The study is also comparing the quality of life of patients and other measures such as the tolerability of the treatments and healthcare costs associated with each intervention. For more information on the SARAH study, please visit: <http://clinicaltrials.gov/ct2/show/NCT01482442>

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) is the most common form of primary liver cancer – cancer that starts in the liver. It is the sixth most common cancer in the world and the second most common cause of cancer-related death¹.

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Nigel Lange
Interim CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

¹ GLOBOCAN 2012. Estimated cancer mortality, incidence and prevalence worldwide.
<http://globocan.iarc.fr/Default.aspx>